Testing

Blood Test for P-Tau217 Estimates Ten-Year Cognitive Impairment Risk

Mayo Clinic researchers paired a blood biomarker with age and genetics to calculate individual risk scores for adults without symptoms.

Published November 18, 2026 Read 3 min 419 words Topic Testing
Reviewed by: Dr. Michael Teplitsky, MD · November 2026

Combining Blood Biomarkers with Age and Genetics

A blood test can estimate future cognitive decline risk up to ten years in advance. Researchers at the Mayo Clinic published the model in the Journal of the American Medical Association Neurology (JAMA Neurology). The tool evaluates adults without current cognitive symptoms.

The prediction tool measures phosphorylated Tau 217 (p-tau217) in blood plasma. It combines that measurement with age, sex, and Apolipoprotein E epsilon 4 (APOE e4) genetic status. This combination provides an individualized probability of progression to mild cognitive impairment (MCI) or dementia.

How Risk Changes with Biomarker Levels and Age

Blood levels of p-tau217 and patient age both drive notable differences in estimated risk. The researchers analyzed 1,644 cognitively unimpaired participants from the Mayo Clinic Study of Aging. They confirmed the association using 534 individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI). All participants were between ages 60 and 90.

A 75-year-old woman without the APOE e4 variant had an estimated five-year MCI risk of 5 percent with low p-tau217. Higher biomarker levels raised that risk to 16 percent. Her ten-year risk rose from 12 percent to 35 percent.

Age produced large changes in risk at identical biomarker levels. With high p-tau217, the estimated five-year MCI risk was 6 percent at age 65. At age 85, that estimate reached 37 percent.

  • Low p-tau217 in a 75-year-old non-carrier corresponded to a 5 percent five-year MCI risk.
  • High p-tau217 in the same individual elevated five-year risk to 16 percent and ten-year risk to 35 percent.
  • At the same elevated biomarker level, five-year MCI risk ranged from 6 percent at age 65 to 37 percent at age 85.

Role in Prevention Trials and Future Care

Absolute risk calculations could help clinicians select candidates for preventive trials before symptoms appear. Previous research relied on Positron Emission Tomography (PET) brain scans to measure amyloid accumulation. Blood tests are less invasive and easier to scale.

Ongoing clinical trials already use blood biomarkers to identify trial participants. The AHEAD 3-45 and TRAILBLAZER-ALZ 3 studies test whether amyloid-clearing therapies delay cognitive decline. Accurate risk estimates help clinicians have informed discussions with patients about the potential benefits and risks of treatment.

Limitations and Current Clinical Recommendations

Medical organizations do not recommend routine biomarker screening for adults without cognitive symptoms. The Mayo Clinic researchers emphasized that their risk estimates require testing in larger, more diverse demographic groups. Different laboratory assays for p-tau217 also require further evaluation to confirm consistency.

Individuals with questions about cognitive health should consult a doctor.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.
Primary source: View original source — referenced for fact-checking; this analysis is independent editorial content.
Found this useful?

Related Articles

Want these markers actually tested and explained?

Opt Health draws 55+ biomarkers at home or at one of 2,000+ lab locations, then a physician sits down with the results and tells you what they mean for you — not just whether they're inside the reference range.

See what Opt Health tests →

Topic updates

Get the weekly lab marker roundup

Blood test interpretation, optimal ranges, fasting insulin, A1C, thyroid panels, testosterone, cortisol, and nutrient markers.

No spam. Unsubscribe anytime.

Understand Your Health Better

Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results